Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Nimbus Therapeutics, Lilly Enter Alliance for Therapeutics for Metabolic Diseases | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances

Nimbus Therapeutics, Lilly Enter Alliance for Therapeutics for Metabolic Diseases

Aim to develop targeted therapies designed to activate a specific isoform of AMPK to improve glucose and lipid homeostas while mitigating safety concerns.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Nimbus Therapeutics has entered a collaboration and licensing agreement with Eli Lilly for potential therapeutics for metabolic diseases with a potential value of $496 million.
 
The two companies will collaborate on the development of novel targeted therapies designed to activate a specific isoform of AMPK for the potential treatment of metabolic diseases. AMPK (AMP-activated protein kinase) is considered a high-value target in this indication due to its role in glucose, lipid metabolism, and inflammation. 
 
The companies will work to identify isoform-selective, small molecule activators of AMPK heterotrimers, believed to improve glucose and lipid homeostasis while mitigating safety concerns.
 
Nimbus will apply its computational drug discovery engine to develop isoform-selective small molecule AMPK activators applicable in a broad range of metabolic diseases, leveraging Lilly’s expertise in this area. 
 
Peter Tummino, Nimbus Therapeutics’ chief scientific officer, said, “Nimbus has established a successful track record in developing and progressing highly-selective small molecules to the clinic against hard-to-interrogate targets, which is a demonstration of the power of our computational and structural approach to drug discovery.”
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics